Top Research Reports for Oracle, Novo Nordisk & Linde

Friday, June 6, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), Novo Nordisk A/S (NVO) and Linde plc (LIN), as well as two micro-cap stocks NVE Corp. (NVEC) and CPS Technologies Corp. (CPSH). The Zacks microcap research is unique, as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets Relieved with Strong Jobs Headline; Revisions LowerToday's Featured Research ReportsOracle’s shares have outperformed the Zacks Computer - Software industry over the past year (+37.4% vs. +15.4%). The company is gaining from ongoing momentum across its cloud business, driven by the strong uptake of Oracle Cloud Infrastructure and Autonomous Database offerings, including from winning cloud-computing contracts from AI-focused startups.The solid adoption of cloud-based applications, comprising NetSuite Enterprise Resource Planning (ERP) and Fusion ERP, bodes well. ORCL’s partnership with Amazon for Oracle Database@AWS and general availability of Oracle Database@Google holds promise. Oracle’s Gen 2 Cloud is driving artificial intelligence clientele. Its share buybacks and dividend policy are noteworthy. The Zacks analyst expects fiscal 2025 net sales to grow 7.7% from fiscal 2024. However, higher spending on product enhancements, toward the cloud platform amid increasing competition in the cloud domain, is likely to limit margin expansion.(You can read the full research report on Oracle here >>>)Shares of Novo Nordisk have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-48.5% vs. -14.7%). The company’s failure to meet the weight-loss target with CagriSema twice has caused Novo a huge setback. Intense competition in the obesity sector also threatens its market share. Patent expiry and pricing pressures across the diabetes market remain headwinds. Nevertheless, Novo Nordisk’s first-quarter earnings match, while revenues miss. Ozempic and Rybelsus for diabetes and Wegovy for obesity are performing well, fueled by increasing demand. Label expansions for the drugs in cardiovascular and other indications will likely boost sales. Novo Nordisk has been tackling the supply constraints of Wegovy by making serious investments to ramp up production. An oral formulation of Wegovy is currently under review by the FDA for obesity. Novo Nordisk is also pursuing other indications, like liver fibrosis and MASH for semaglutide.(You can read the full research report on Novo Nordisk here >>>)Linde’s shares have outperformed the Zacks Chemical - Specialty industry over the past year (+9.7% vs. +3%). The company remains a dominant player in the industrial gas sector, delivering strong financial performance with consistent EPS growth, disciplined capital allocation, and industry-leading margins. Its record $10 billion backlog ensures long-term revenue stability, while sustainability initiatives position it as a leader in low-carbon energy solutions. Strategic investments in high-return projects and small on-site contracts further reinforce its competitive edge. However, foreign exchange headwinds, softening industrial demand in Europe & China, and regulatory uncertainties pose challenges. Also, slower growth in healthcare impacts diversification efforts. Despite these risks, LIN's strong execution, efficiency improvements, & long-term contracts position it well for sustained profitability & resilience in fluctuating market conditions.(You can read the full research report on Linde here >>>)Shares of NVE have underperformed the Zacks Electronics - Semiconductors industry over the past year (-1.8% vs. +25.9%). This microcap company with a market capitalization of $345.33 million have a 13% year-over-year revenue decline, rising costs and increased inventory raise concerns about demand softness and cost control. Customer concentration, especially dependence on Abbott, adds risk ahead of a key contract expiry in December 2025.Nevertheless, NVE Corp offers a compelling investment case, driven by exceptional profitability, with the fiscal 2025 gross margin rising to 84% and the operating margin at 62%, aided by a favorable product mix and direct sales strategy. A debt-free balance sheet, $52 million in liquid assets and disciplined capital allocation, including consistent dividends, highlight financial strength. Strategic capex supports next-gen manufacturing scale-up, enhancing margin leverage. Additionally, NVEC’s proprietary spintronics tech enables leadership in high-performance sensing for medtech and industrial IoT. (You can read the full research report on NVE here >>>)CPS Technologies’ shares have outperformed the Zacks Electronics - Miscellaneous Components industry over the past year (+64.4% vs. -4.9%). This microcap company with a market capitalization of $40.96 million is leveraging contract wins and defense-funded R&D to build a diversified, innovation-driven revenue base. The $13.3-million AlSiC contract and five active SBIR awards support visibility through 2025, with the commercialization of advanced materials like radiation shielding and fiber-reinforced aluminum offering future upside. A third production shift has driven revenue and gross margin recovery, though yields remain pressured. CPSH is positioned to benefit from megatrends in electrification, thermal management and defense modernization. However, profitability is sensitive to volume and mix, with limited long-term contract coverage, early-stage product risk, working capital inefficiencies and ongoing labor volatility. The absence of high-margin armor revenues post-2024 further tempers near-term margin expansion.(You can read the full research report on CPS Technologies here >>>)Other noteworthy reports we are featuring today include Arista Networks Inc (ANET), Constellation Energy Corp. (CEG) and AutoZone, Inc. (AZO).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadOracle (ORCL) Gains from Cloud Suite Adoption & PartnershipsGLP-1 Drugs Boost Novo Nordisk (NVO), Market Rivalry a WoeLinde (LIN) Banks on $10B Gas Backlog for Long-Term GrowthFeatured ReportsArista (ANET) Rides on Strong Demand, Product InnovationPer the Zacks analyst, solid traction in the data Center and cloud networking vertical will likely boost Arista's top line. Focus on developing solutions for AI networking architecture is a positive.Focus on Renewable Energy Aid Constellation Energy (CEG)Per the Zacks analyst, Constellation Energy gains from expansion of renewable portfolio. Its position as an industry leader in the safe operation of nuclear plants helps it increase its nuclear outputExpansion of Mega Hubs Aids AutoZone (AZO) Amid Rising CapExPer the Zacks analyst, AutoZone's focus on increasing market penetration via the expansion of mega hubs is set to boost its long-term prospects. However, high capex remains a concern.Organic Growth Aids Cencora (COR) Amid CompetitionPer the Zacks analyst, Cencora should benefit from continued solid organic revenue growth, World Courier unit and Specialty distribution business amid cutthroat competition in the Medtech space.CoStar Group (CSGP) Rides on Strong Subscription RevenuesPer the Zacks analyst, CoStar Group's resilient and diversified subscription business is expected to drive growth. It benefits from a robust portfolio of marketplaces.Solid Demand Aid Alexandria (ARE) Amid High Interest ExpensePer the Zacks Analyst, ARE is set to gain from its portfolio of Class A/A+ properties amid rising demand for life science assets propelling leasing activity. Yet high interest expenses raises concern.HEPACO Buyout Benefits Clean Harbors (CLH), Competition HighPer the Zacks analyst, HEPACO acquisition expanded Clean Harbors' Environmental Services segment's field services business. High competition lowers pricing power and increases operational expenses.New UpgradesBill Holdings (BILL) Rides on Strong SMB Business clientelePer the Zacks analyst, Bill is benefiting from an expanding small and medium business clientele, as well as a diversified business model.Store Footprint Optimization Program to Aid Advance AutoThe Zacks analyst believes that this strategic shift will boost Advance Auto's focus on high-performing regions and set the stage for robust growth and greater share of the aftermarket opportunity.Strong Demand & Digitization Aid Marriott Vacations (VAC)Per the Zacks analyst, Marriott Vacations is likely to benefit from solid leisure demand, digital initiatives and expansion efforts. Also, focus on the Business Modernization Initiative bode well. New DowngradesUnitedHealth Group (UNH) Continues to Suffer From High CostsPer the Zacks Analyst, the company's elevated operating costs have been putting pressure on its margins. A debt-laden balance sheet induces an increase in interest expenses.Rising Net Outflows, Concentration Risk Hurt Lazard (LAZ)Per the Zacks analyst, rising net outflows hurt Lazard's assets under management growth. Also, high dependence on financial advisory revenues is a concern, due to uncertainty in global markets.Soft International Business is a Concern for Zumiez (ZUMZ) Per the Zacks analyst, Zumiez's International segment continued to struggle in the first quarter, facing persistent challenges in Europe. Comparable sales in this segment declined by 2.3% in Q1.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report Oracle Corporation (ORCL): Free Stock Analysis Report Linde PLC (LIN): Free Stock Analysis Report NVE Corporation (NVEC): Free Stock Analysis Report CPS Technologies Corp. (CPSH): Get Free ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks